VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Beam Therapeutics Inc. $BEAM

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 38,131 shares of the company’s stock, valued at approximately $1,309,000.

Several other institutional investors have also made changes to their positions in BEAM. Alphabet Inc. bought a new position in shares of Beam Therapeutics during the 2nd quarter worth approximately $11,037,000. Canal Insurance CO acquired a new position in shares of Beam Therapeutics in the 1st quarter worth approximately $953,000. Ishara Investments LP bought a new stake in Beam Therapeutics during the 4th quarter worth approximately $1,386,000. Janus Henderson Group PLC grew its position in Beam Therapeutics by 136.1% during the 1st quarter. Janus Henderson Group PLC now owns 93,253 shares of the company’s stock worth $2,222,000 after acquiring an additional 53,752 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in Beam Therapeutics by 111.0% during the 1st quarter. First Trust Advisors LP now owns 135,166 shares of the company’s stock valued at $3,221,000 after purchasing an additional 71,110 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

More Beam Therapeutics News

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Analysts maintain bullish views. Wedbush reaffirmed its Buy/Outperform rating, while Canaccord Genuity and JonesTrading also maintained Buy ratings. Separately, the brokerage consensus remains “Moderate Buy,” supporting investor confidence in Beam’s pipeline and long-term prospects. Wedbush Reaffirms Their Buy Rating Wedbush Reiterates Outperform Rating Consensus Moderate Buy Rating
• Positive Sentiment: BEAM-302 data show sustained biomarker improvement. Updated Phase 1/2 results in alpha-1 antitrypsin deficiency indicated that the investigational treatment restored AAT levels, with biomarker follow-up extending to 18 months. The results strengthen the case for continued development, although the study remains early stage and clinical benefit has not yet been conclusively established. BEAM-302 Clinical Data Analysis
• Neutral Sentiment: Options activity increased. Unusually large options trading was reported, which may signal heightened speculation or hedging but does not establish a clear directional outlook for BEAM. Unusually Large Options Trading
• Neutral Sentiment: Reports of a sharp increase in short interest showed zero shares both before and after the period, suggesting a data-quality issue rather than a meaningful change in bearish positioning.
• Negative Sentiment: Pomerantz LLP is investigating potential investor claims. The law firm’s announcement may add legal and headline risk, although it does not allege that Beam has been found liable. Pomerantz Investor Investigation

Insider Activity

In other Beam Therapeutics news, insider Amy Simon sold 16,667 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the completion of the sale, the insider directly owned 85,696 shares of the company’s stock, valued at approximately $2,205,815.04. The trade was a 16.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Fmr Llc sold 251,488 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the transaction, the insider owned 854,583 shares in the company, valued at approximately $30,132,596.58. The trade was a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 301,527 shares of company stock worth $10,468,500. 3.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Tuesday, August 25th. Bank of America restated a “buy” rating and set a $47.00 target price on shares of Beam Therapeutics in a report on Wednesday, July 8th. Wedbush restated an “outperform” rating and issued a $65.00 target price on shares of Beam Therapeutics in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Beam Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $49.00.

Beam Therapeutics Stock Performance

BEAM stock opened at $23.99 on Friday. The company has a 50 day moving average price of $28.50 and a 200 day moving average price of $28.88. Beam Therapeutics Inc. has a fifty-two week low of $20.23 and a fifty-two week high of $38.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 14.57 and a quick ratio of 14.57. The stock has a market capitalization of $2.48 billion, a PE ratio of -27.90 and a beta of 2.22.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The firm’s quarterly revenue was down 94.2% on a year-over-year basis. During the same period last year, the business posted ($1.00) earnings per share. Analysts forecast that Beam Therapeutics Inc. will post -4.49 EPS for the current year.

Beam Therapeutics Profile

Beam Therapeutics Inc is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers.